Author/Authors :
Lampaki, Sofia Aristotle University of Thessaloniki - ``G Papanikolaou`` General Hospital - Pulmonary Deparment-Oncology Unit, Greece , Kioumis, Ioannis Aristotle University of Thessaloniki - ``G Papanikolaou`` General Hospital - Pulmonary Deparment-Oncology Unit, Greece , Pitsiou, Georgia Aristotle University of Thessaloniki - ``G Papanikolaou`` General Hospital - Pulmonary Deparment-Oncology Unit, Greece , Lazaridis, George ``G. Papageorgiou`` Hospital - Oncology Department, Greece , Syrigos, Konstantinos University of Athens - ``Sotiria`` Hospital of Chest Diseases - Oncology Department, Greece , Trakada, Georgia National University of Athens - Medical School - Department of Clinical Therapeutics, Division of Pneumonology, Greece , Kakolyris, Stylianos Democritus University of Thrace - University General Hospital of Alexandroupolis - Oncology Department, Greece , Zarogoulidis, Konstantinos Aristotle University of Thessaloniki - ``G Papanikolaou`` General Hospital - Pulmonary Deparment-Oncology Unit, Greece , Mpoukovinas, Ioannis ``Sotiria`` Hospital of Chest Diseases - Pulmonary Deparment-Oncology Unit, Greece , Rapti, Aggeliki Biomedicine Private Laboratory - Oncology Department, Greece , Zarogoulidis, Paul Aristotle University of Thessaloniki - ``G Papanikolaou`` General Hospital - Pulmonary Deparment-Oncology Unit, Greece
Abstract :
It has been observed that lung cancer either non-small cell or small cell is responsible for eye metastases. This form of metastases in several cases was the first manifestation of the disease and further investigation led to the diagnosis of the underlying malignancy. Both types of lung cancer are equally responsible for this demonstration. Furthermore; both chemotherapy and tyrosine kinase inhibitors have shown equal positive results in treating the exophalmos manifestation. Up to date information will be presented in our current work.
Keywords :
Exophalmos , Metastases , NSCLC , SCLC
